“TPX-0005 has demonstrated clinically meaningful and durable benefit in patients with ROS1 fusion-positive lung cancers and NTRK fusion-positive tumors,” said Alexander Drilon, M.D., a key investigator in the TRIDENT-1 Study and Clinical Director of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center. “I continue to be encouraged by the preliminary antitumor activity … Continue reading TP Therapeutics Announces Interim Data from the Phase 1/2 Clinical Trial of Investigational Agent TPX-0005 at ASCO 2018: Data Presented from the Ongoing TRIDENT-1 Study
NICE have published a guidance for Pfizer’s Xalkori drug to treat ROS1-postivie non-small cell lung cancer has been made available via the Cancer drugs fund. Head of Oncology at Pfizer UK Craig Eagle commented on the news, “The decision to make the drug available is good news for patients in England. We are committed to … Continue reading Pfizer new lung cancer drug is successful for funding.
You’ve likely never heard the story of how three young women, who call themselves “ROS1ders” from a rare form of lung cancer they share, may be turning the nation’s 46-year-old war on cancer on its head. The women were diagnosed with a gene mutation called a ROS1 fusion. Read more here
“We reviewed clinicopathological data of patients with ROS1-rearrangement who received crizotinib therapy at our institution between April 2014 and December 2016. ROS1 fusion partners were evaluated using Sanger sequencing for tumor tissue available.” Read the entire article here
“A University of Colorado Cancer Center study published today in the journal Clinical Cancer Research provides an in-depth look at how these ALK+ and ROS1+ cancers evolve to resist treatment. A second study demonstrates the ability to identify these changes in patient blood samples, perhaps easing the ability to monitor patients for these changes that … Continue reading Two Colorado studies find resistance mechanisms in ALK+ and ROS1+ cancers
Since I’ve been holding steady on my treatment, I haven’t needed access to a clinical trial yet. However, clinical trials may become essential to my survival, and I’m already concerned about getting into them when I need help the most. I often hear scientists ask, “how can we increase patient participation in clinical trials so … Continue reading The Unnecessary Cruelty of Clinical Trials by: Lisa Goldman